| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Departments of Medical Biochemistry [A. H., S. O., To. K., Ta. K., M. K., M. O.] and Urology [S. N.], Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
are not the only specific ligands for EGFR; heparin-binding EGF, epiregulin, betacellulin, and amphiregulin, and bind to EGFR. Homodimerization of EGFR molecules as well as heterodimerization of EGFR with other EGFR family including HER-2/neu induces ligand-specific activation of a number of intracellular signal transduction cascades such as phospholipase C
, phosphatidylinositol-3'-kinase, small G-proteins, Ras, the Ras GTPase-activating protein, growth factor receptor-binding protein 2, and Src family kinases (2)
, STAT, and Akt. EGFR, with its mitogenic influence, can contribute to the acquisition/development of malignant phenotypes. Moreover, EGFR activation plays a key role in cell adhesion, cell locomotion, and cell survival, invasion, and angiogenesis, which results in modulation of tumor progression (3)
.
The development and progression of malignant cancer is closely linked to aberrant EGFR signaling in various tumor types (2)
. Various mechanisms are likely to be involved in aberrant EGFR signaling: (a) ligand-independent tyrosine kinase activation of EGFR is often caused by the development of the constitutively active receptor mutants, and this mutation is observed in various tumor types such as glioma, non-small cell lung cancer, and carcinomas of prostate, breast, ovary, and stomach (2
, 4)
; (b) overexpression of ligands induces activation of normal EGFR: TGF, which is overproduced by many different tumor types, enhances EGFR signaling as part of an autocrine loop; and (c) overexpression of wild-type EGFR may result from increased transcriptional or posttranscriptional mechanisms or gene amplification, and this has been associated with invasiveness, frequency of relapse, and prognosis in esophageal cancer, breast cancer, and other cancers (1)
. EGFR levels in human malignant cells are also critical for limiting sensitivity to several anticancer agents (5, 6, 7)
. EGFR is expected to be a valuable molecular target for development of novel and effective anticancer agents.
Tyrosine-kinase-targeting anticancer agents of the EGFR family that are currently under investigation include antibodies that block ligand binding to the extracellular region of the receptor, EGF/TGF-toxin conjugates that target the extracellular ligand-binding region of the receptor, and tyrosine kinase inhibitors that act at the level of the intracellular receptor tyrosine kinase (2
, 8, 9, 10)
. A recent highlight is the development of quinazoline-derived agents that are specific ATP-competitors of EGFR tyrosine kinase, one representative of which is ZD1839 (or Iressa; Ref. 11
). ZD1839 shows antiproliferative activity in various human cancer cell types in vitro (12)
. Tumor growth inhibition in vivo by ZD1839 is potentiated by combination with a variety of cytotoxic anticancer agents (12
, 13)
. ZD1839 is currently in Phase II and III clinical trials in cancer patients (11)
.
EGFR activation is often linked with invasion, metastasis, and angiogenesis; therefore, these processes might be affected by EGFR inhibition with ZD1839 (3)
. Several studies have shown that blockage of EGFR activation, by either antibodies or tyrosine kinase inhibitors, causes dose-dependent inhibition of production of the angiogenesis-related factors VEGF, TGF, bFGF, and IL-8 in tumor cells, resulting in the modulation of angiogenesis (14, 15, 16, 17, 18, 19, 20)
. However, it remains unclear whether the blockage of EGFR signaling directly correlates with the inhibition of angiogenesis. In our present study, we used various angiogenesis models in vitro and in vivo to determine how angiogenesis is modulated by ZD1839.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Cell Culture
Human microvascular endothelial cells were isolated from normal omental tissue that was removed during surgery with informed consent under an institutional review board-approved protocol, and cells were cultured in M199 supplemented with 10% FBS, 60 µg/ml kanamycin and 60 µg/ml penicillin (21)
. We used cells at passage 3–5 because of the responsiveness of the endothelial cells to growth factors such as EGF during serial cultivation (22)
. HUVE cells purchased from Clonetics Inc (South San Francisco, CA) were cultured according to the manufacturers’ instructions. Human vulvar squamous carcinoma A431 cells were cultured in DMEM supplemented with 10% FBS. Human epidermoid cancer cells, KB3-1, were cultured in MEM supplemented with 10% newborn calf serum. The cells were maintained under standard cell culture conditions at 37°C and 5% CO2 in a humid environment.
Cell Migration Assay
For the cell migration assays we used two assay systems with two kinds of primary endothelial cells: HUVE cells, which respond to VEGF, and human microvascular endothelial cells, which respond to EGF.
Migration Assay under Coculture System.
To assay for migration of human endothelial cells (23, 24, 25)
, A431 cells were grown in the outer chamber and then preincubated with various concentrations of ZD1839 or SU5416 followed by stimulation with 20 ng/ml EGF at 37°C. After 24 h, HUVE cells (3 x 105) were suspended in medium supplemented with 0.5% FBS and were seeded in the inner chamber with polycarbonate filters (8 µm pores; Kurabo Inc, Tokyo, Japan) coated with human plasma fibronectin (1.33 µg/ml; Life Technologies, Inc.). After a 4-h incubation at 37°C, media in the inner chambers were aspirated, and cells on the upper surface of the filter were removed with a cotton swab. Cells on the lower surface were fixed with methanol and were stained with Giemsa. The stained nuclei were counted. Five fields (xl00) per chamber were counted, and average numbers were determined from assays with three chambers.
Migration Assay of Human Microvascular Endothelial Cells.
This migration assay was performed with a multiwell chamber as the outer chamber. Polycarbonate filters (8 µm pores) were coated with 1.33 µg/ml fibronectin for l h at 37°C and used as the inner chamber (26)
. Human microvascular endothelial cells (3 x 105) were suspended in M199 containing 0.5% FBS and were seeded in the inner chamber. In the outer chamber, serial dilutions of ZD1839 with or without EGF (20 ng/ml) in the same medium were added. After incubation for 4 h at 37°C, nonmigrated cells on the upper surface of the filter were removed, and the cells that had migrated under the filter were counted. Five fields (x100) per chamber were counted, and average numbers were determined from assays with three chambers.
Quantitative Analysis of Tube Formation in Endothelial Cells on Type I Collagen Gel
The tube formation assay was performed as described previously (23
, 27, 28, 29)
. In brief, human microvascular endothelial cells were plated onto type I collagen gel in a medium containing 10% FBS. When the cells reached confluence, that medium was replaced with a medium containing 1% FBS, with or without 20 ng/ml EGF and the various doses of ZD1839, and the cells were incubated for an additional 72 h. On the 3rd day, phase-contrast micrographs (x200) were recorded using a still video camera recorder (R5000H; Fuji, Tokyo, Japan). The total length of the tube-like structures was measured for each field using a Cosmozone image analyzer (Nikon, Tokyo, Japan). Eight random fields were measured for each dish.
Corneal Micropocket Assay in Mice and Quantification of Corneal Neovascularization
The corneal micropocket assay was performed essentially as described previously (30)
. Briefly, 0.3 µl of Hydron pellets (IFN Sciences, New Brunswick, NJ) containing human EGF (200 ng) or murine VEGF (200 ng) were prepared and implanted in the corneas of male BALB/c mice. ZD1839 was administered by adding directly to the growth factor/Hydron solution (20 ng/pellet) or by injecting i.p. (50 mg/kg/day) on days 1–6.
SU5416 was administrated by i.p. injection (25 mg/kg/day) on days 1–6. On day 7, mice were sacrificed and their corneal vessels were photographed. Images of the corneas were recorded using Nikon Coolscan software with standardized illumination, contrast, and threshold settings, and were saved on disk. Areas of corneal neovascularization were analyzed using the software package NIH Image 1.61 (31) and were expressed in mm2.
ELISA of VEGF and IL-8
The concentration of VEGF and IL-8 in the conditioned medium of the human cancer cell lines A431 and KB3-1 and the human microvascular endothelial cells were measured using commercially available ELISA kits (32)
. These cells were plated in 24-well dishes in a medium containing 10% FBS. When the cells reached subconfluence, the medium was replaced with a serum-free medium for 24 h. The cells were then incubated with various concentrations of ZD1839 for 3 h followed by 20 ng/ml EGF at 37°C. Assays were performed after 24-h incubation with serum-free conditioned medium. Results were normalized for the number of cells and reported as picograms of growth factor/106 cells/24 h.
Western Blot Analysis
A431 or KB3–1 cells were cultured in serum-free medium, and human microvascular endothelial cells were cultured in medium containing 0.5% FBS for 24 h. The cells were then incubated with ZD1839 at concentrations increasing from 0 to 1 µM for 3 h before 20-ng/ml EGF stimulation for 15 min at 37°C. The cells were then rinsed with ice-cold PBS and lysed in Triton X-100 buffer (50 µM HEPES, 150 µM NaCl, 1% Triton X-100, and 10% glycerol containing l mM PMSF, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and 1 mM sodium vanadate). Cell lysates were subjected to SDS PAGE and transferred to Immobilon membranes (Millipore, Bedford, MA). After transfer, blots were incubated with the blocking solution and probed with anti-EGFR antibody, anti-phospho-EGFR antibody, anti-ERK 1/2 antibody, anti-phospho-ERK 1/2 antibody, anti-STAT1 antibody, anti-phospho-STAT1 antibody, anti-Akt antibody and anti-phospho-Akt antibody, followed by washing. The protein content was visualized using horseradish peroxidase-conjugated secondary antibodies followed by enhanced chemiluminescence (ECL; Amersham).
Statistical Analysis
Statistical comparisons were performed using Mann-Whitney’s test; P 
0.05 was considered significant.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. ZD1839 (0.05 µM) inhibited the EGF-induced EGFR autophosphorylation by >80% and, at 0.5 µM, almost completely blocked the autophosphorylation. ZD1839 at 0.5 µM almost completely inhibited a downstream EGFR signaling transduction pathway, EGF-dependent phosphorylation of ERK 1 and ERK 2 (Fig. 1)
.
|
, treatment of A431 and KB3–1 cells with EGF enhanced production of VEGF about 3- to 4-fold over the untreated control; ZD1839 at 0.5 µM almost completely inhibited this EGF-induced VEGF production. The production of IL-8 was enhanced more than 10-fold by EGF, and almost completely blocked by ZD1839 at 0.5 µM.
|
(33
, 34)
. We have observed that EGF also enhanced expression of VEGF, and that ZD1839 blocked the EGF-dependent production of VEGF in human microvascular endothelial cells (data not shown).
ZD1839 Inhibits Migration by Vascular Endothelial Cells in Vitro.
Cell proliferation and migration and tube formation of vascular endothelial cells is requisite for the development of neovasculatures. We constructed a cell migration assay system under cocultivation with cancer cells in a double-chamber model (Fig. 3A)
. HUVE cells, when alone, demonstrated no enhancement of cell migration in the presence of EGF (Fig. 3B)
. However, when HUVE and A431 cells were both present, EGF enhanced the migration of HUVE cells. ZD1839 at 0.5 µM or SU5416 at 5 µM almost completely inhibited the cell migration by HUVE cells in response to EGF. Under the coculture conditions, HUVE cells did not respond to EGF, and SU5416 at 5 µM inhibited cell migration completely. ZD1839 thus inhibited HUVE cell migration through blockage of EGF-induced VEGF production from A431 cells (Fig. 3B)
.
|
.
ZD1839 Inhibits Downstream Signaling of EGFR and Formation of Tube-like Structures by Microvascular Endothelial Cells in Vitro.
In the presence of EGF/TGF, EGFR in human microvascular endothelial cells becomes highly phosphorylated, and the cells form tube-like structures in collagen gel (22
, 24
, 27)
. Consistent with our previous study (22)
, EGFR in microvascular endothelial cells was markedly phosphorylated by EGF (Fig. 4)
. ZD1839, at 0.5-l µM, almost completely inhibited the EGF-dependent EGFR autophosphorylation and, at 0.5 µM, completely inhibited the downstream signaling ERK 1/2 and Akt phosphorylation. Even at 0.05 µM, ZD1839 could inhibit phosphorylation of another EGFR downstream signaling molecule (STAT1).
|
. ZD1839 thus appeared to inhibit both the cell migration and the formation of tube-like structures by microvascular endothelial cells in vitro.
|
. Administration of ZD1839 blocked the EGF-induced neovascularization when the drug was administered not only as pellets but also i.p. Daily i.p. administration of SU5416 also inhibited EGF-induced neovascularization, but its inhibition appeared to be less than that of ZD1839. In contrast, VEGF-induced neovascularization was inhibited by the administration of SU5416 but not of ZD1839 (Fig. 6)
.
|
. There appeared to be no inhibition by ZD1839 of VEGF-induced neovascularization, whereas about 70% inhibition compared with control was observed after i.p. administration of SU5416 (Fig. 7)
.
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
EGFR activation is expected to modulate various critical processes in the development, maintenance, and spread of malignant tumors, such as invasion, metastasis, and angiogenesis (3
, 35)
. TGF and EGF are potent inducers of angiogenesis, and coexpression of EGFR and TGF is closely associated with microvessel density in invasive cancers (36
, 37)
. Various oncogenes such as H-ras, v-src, polyoma middle T antigen, and fos/jun can modulate expression of EGFR (38, 39, 40)
, which suggests a close correlation between EGFR activity and malignant states. We have previously reported that EGF/TGF induces cell migration and formation of tube-like structures by human microvascular endothelial cells (21
, 22
, 27 , 30)
. Moreover, expression of metalloproteinases and plasminogen activator is enhanced in human microvascular endothelial cells in vitro by EGF/TGF (41, 42, 43)
. Under cocultivation conditions, using an angiogenesis model system with a double chamber, human microvascular endothelial cells form tube-like structures by the production of TGF from cocultivated human glioma cells or esophageal cancer cells (24
, 44)
. Hence, either EGF or TGF can induce various angiogenic stimuli, not only from cancer cells but also from endothelial cells that express EGFR, which supports previous reports that TGF and EGF are angiogenic factors (37
, 45)
. The EGFR thus appears to play a key role in the angiogenic response to EGF/TGF. Our present study indicates that the EGF-induced formation of tube-like structures by human microvascular endothelial cells in type I collagen gel is blocked by ZD1839. ZD1839 thus directly inhibits EGF-induced angiogenesis, possibly through the blockade of EGF/TGF-EGFR signaling.
Phosphorylation of two downstream signaling molecules of EGFR, ERK 1/2 and Akt, was completely inhibited by ZD1839 at 0.5 µM in microvascular endothelial cells. ZD1839 (0.05 µM) appeared to cause almost complete inhibition of EGF-induced STAT1 phosphorylation. These data suggest that STAT1 phosphorylation is more sensitive to inhibition by ZD1839 than is phosphorylation of either ERK 1/2 or Akt. It remains unclear how the inhibition of STAT1 signaling is associated with the antiangiogenic activity of ZD1839 and the reasons for the sensitivity of this pathway to ZD1839.
The two cancer cell lines (A431 and KB3-1) produced higher amounts of VEGF and IL-8 in response to EGF than the human microvascular endothelial cells. However, we did not observe a significant stimulation of bFGF production by EGF in the cancer cell lines (data not shown). The EGF-dependent production of VEGF and IL-8 was markedly blocked by ZD1839. Consistent with our result, the inhibition of EGFR activation by a specific antibody or an EGFR tyrosine kinase inhibitor has been shown to reduce production of VEGF, bFGF, IL-8, and TGF in various cancer cell types (14, 15, 16, 17, 18, 19, 20)
. Migration of HUVE cells, which don’t respond to EGF, was stimulated when human cancer cells were cocultivated in the presence of EGF, and this EGF-dependent migration was almost completely blocked by ZD1839 and SU5416. Moreover, angiogenesis in vivo was markedly induced by EGF, and this angiogenesis was inhibited completely by ZD1839 and partially by SU5416. It has been reported that the IC50 of SU5416 against VEGF receptor-2 (KDR/F1k-1) tyrosine kinase is 1.3 ± 0.8 µM and against EGFR tyrosine kinase is >100 µM (46)
. Administration of SU5416, but not ZD1839, inhibited VEGF-induced angiogenesis in mice.
We have previously reported that the inflammatory cytokines TNF and IL-1 enhances production of VEGF, IL-8, bFGF, and metalloproteinases from vascular endothelial cells or cancer cells (32
, 33
, 34
, 47) , and also that these angiogenesis-related factors appear to play a key role in angiogenesis by TNF or IL-l under autocrine/paracrine control (48)
. Similar paracrine and/or autocrine controls could operate through the interaction of EGF/TGF with EGFR; and VEGF, IL-8, and other angiogenesis-related factors are expected to be involved in EGF-induced angiogenesis (see Fig. 8
). The partial inhibition of EGF-induced angiogenesis in vivo as well as in vitro by SU5416 might be partly attributable to reduced production of angiogenic factors, in particular VEGF. Using various angiogenesis assay models, we found that EGF/TGF-induced angiogenesis might be attributable to its signaling through direct interaction with vascular endothelial cells, and also to angiogenesis-related factors, such as VEGF, IL-8, and others, that are produced from cancer cells and, possibly, from vascular endothelial cells (Fig. 8)
.
|
with EGFR and its family of proteins can affect not only cell proliferation and tumor growth but also invasion, metastasis, and angiogenesis. ZD1839 is, thus, expected to have inhibitory effects on all of these biological processes, not only in cancer cells but also in endothelial cells through inhibition of EGF/TGF-EGFR signaling. This study demonstrates that ZD1839 shows antiangiogenic activity in vitro as well as in vivo.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 Supported by a grant-in-aid on cancer research from Ministry of Education, Culture, Sports, Science and Technology, Japan. "Iressa" is a trademark of the AstraZeneca group of companies. 
2 To whom requests for reprints should be addressed, at Department of Medical Biochemistry, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. Phone: 81-92-642-6098; Fax: 81-92-642-6203; E-mail: mayumi{at}biochem1.med.kyushu-u.ac.jp
3 The abbreviations used are: EGF, epidermal growth factor; EGFR, EGF receptor; bFGF, basic fibroblast growth factor; ERK, extracellular signal-regulated kinase; FBS, fetal bovine serum; HUVE, human umbilical vein endothelium; IL, interleukin; STAT, signal transducer and activator of transcription; TGF, transforming growth factor ; TNF, tumor necrosis factor ; VEGF, vascular endothelial growth factor; KDR, kinase domain containing receptor; Flk-1, fetal liver kinase 1.
Received 10/30/01. Accepted 3/ 5/02.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
in tube formation of human microvascular endothelial cells induced by esophageal cancer cells. Biochem. Biophys. Res. Commun., 186: 1471-1479, 1992.[Medline]
. Biochem. Biophys. Res. Commun., 189: 601-609, 1992.[Medline]
B in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol. Cell. Biol., 16: 4231-4239, 1996.[Abstract]
and vascular endothelial growth factor during inflammatory neovascularization in the mouse cornea. Angiogenesis, 3: 327-334, 1999.[Medline]
and IL-1. Int. J. Cancer, 85: 182-188, 2000.[Medline]
-dependent angiogenesis. Mol. Cell. Biol., 17: 4015-4023, 1997.[Abstract]
in human glioma cells. Possible roles of SP-1. J. Biol. Chem., 271: 28220-28228, 1996.This article has been cited by other articles:
|
|
 |
|
  A. Bozec, A. Sudaka, N. Toussan, J.-L. Fischel, M.-C. Etienne-Grimaldi, and G. Milano Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model Ann. Onc., October 1, 2009; 20(10): 1703 - 1707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Qayum, R. J. Muschel, J. H. Im, L. Balathasan, C. J. Koch, S. Patel, W. G. McKenna, and E. J. Bernhard Tumor Vascular Changes Mediated by Inhibition of Oncogenic Signaling Cancer Res., August 1, 2009; 69(15): 6347 - 6354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Pennell and T. J. Lynch Jr. Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC Oncologist, April 1, 2009; 14(4): 399 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Dickler, H. S. Rugo, C. A. Eberle, E. Brogi, J. F. Caravelli, K. S. Panageas, J. Boyd, B. Yeh, D. E. Lake, C. T. Dang, et al. A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer Clin. Cancer Res., December 1, 2008; 14(23): 7878 - 7883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. de Langen, V. E. M. van den Boogaart, J. T. Marcus, and M. Lubberink Use of H215O-PET and DCE-MRI to Measure Tumor Blood Flow Oncologist, June 1, 2008; 13(6): 631 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Normanno and A. De Luca Erlotinib in Pancreatic Cancer: Are Tumor Cells the (only) Target? J. Clin. Oncol., December 20, 2007; 25(36): 5836 - 5837. [Full Text] [PDF]
|
|
|
|
|
|
C. Gridelli, P. Maione, A. Rossi, and F. De Marinis The Role of Bevacizumab in the Treatment of Non-Small Cell Lung Cancer: Current Indications and Future Developments Oncologist, October 1, 2007; 12(10): 1183 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zhu, X. Jia, G. Xiao, Y. Kang, N. C. Partridge, and L. Qin IMPLICATIONS FOR OSTEOLYTIC BONE METASTASES J. Biol. Chem., September 14, 2007; 282(37): 26656 - 26664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sandler Bevacizumab in Non Small Cell Lung Cancer Clin. Cancer Res., August 1, 2007; 13(15): 4613s - 4616s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. O. Hanrahan and J. V. Heymach Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vandetanib (ZD6474) and AZD2171 in Lung Cancer Clin. Cancer Res., August 1, 2007; 13(15): 4617s - 4622s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Li, Y.-H. Ling, I. D. Goldman, and R. Perez-Soler Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non-Small Cell Lung Cancer Cells Clin. Cancer Res., June 1, 2007; 13(11): 3413 - 3422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Wu, A. Onn, T. Isobe, S. Itasaka, R. R. Langley, T. Shitani, K. Shibuya, R. Komaki, A. J. Ryan, I. J. Fidler, et al. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade Mol. Cancer Ther., February 1, 2007; 6(2): 471 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ono and M. Kuwano Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and Response to Gefitinib and Other EGFR-Targeting Drugs Clin. Cancer Res., December 15, 2006; 12(24): 7242 - 7251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sandler and R. Herbst Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin. Cancer Res., July 15, 2006; 12(14): 4421s - 4425s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Zania, S. Kritikou, C. S. Flordellis, M. E. Maragoudakis, and N. E. Tsopanoglou Blockade of Angiogenesis by Small Molecule Antagonists to Protease-Activated Receptor-1: Association with Endothelial Cell Growth Suppression and Induction of Apoptosis J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 246 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Maruyama, M. Ono, A. Kawahara, T. Yokoyama, Y. Basaki, M. Kage, S. Aoyagi, H. Kinoshita, and M. Kuwano Tumor Growth Suppression in Pancreatic Cancer by a Putative Metastasis Suppressor Gene Cap43/NDRG1/Drg-1 through Modulation of Angiogenesis. Cancer Res., June 15, 2006; 66(12): 6233 - 6242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-i. Ueda, Y. Basaki, M. Yoshie, K. Ogawa, S. Sakisaka, M. Kuwano, and M. Ono PTEN/Akt Signaling through Epidermal Growth Factor Receptor Is Prerequisite for Angiogenesis by Hepatocellular Carcinoma Cells That Is Susceptible to Inhibition by Gefitinib. Cancer Res., May 15, 2006; 66(10): 5346 - 5353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Normanno and W. J Gullick Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application? Endocr. Relat. Cancer, March 1, 2006; 13(1): 3 - 6. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Maione, C. Gridelli, T. Troiani, and F. Ciardiello Combining Targeted Therapies and Drugs with Multiple Targets in the Treatment of NSCLC. Oncologist, March 1, 2006; 11(3): 274 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Hall, F. R. Westwood, and P. F. Wadsworth Review of the Effects of Anti-Angiogenic Compounds on the Epiphyseal Growth Plate Toxicol Pathol, February 1, 2006; 34(2): 131 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yano, H. Muguruma, Y. Matsumori, H. Goto, E. Nakataki, N. Edakuni, H. Tomimoto, S. Kakiuchi, A. Yamamoto, H. Uehara, et al. Antitumor Vascular Strategy for Controlling Experimental Metastatic Spread of Human Small-Cell Lung Cancer Cells with ZD6474 in Natural Killer Cell-Depleted Severe Combined Immunodeficient Mice Clin. Cancer Res., December 15, 2005; 11(24): 8789 - 8798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bozec, P. Formento, J. Ciccolini, R. Fanciullino, L. Padovani, X. Murraciole, J.-L. Fischel, and G. Milano Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation Mol. Cancer Ther., December 1, 2005; 4(12): 1962 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E.W. Cohen, M. A. Kane, M. A. List, B. E. Brockstein, B. Mehrotra, D. Huo, A. M. Mauer, C. Pierce, A. Dekker, and E. E. Vokes Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., December 1, 2005; 11(23): 8418 - 8424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Solomon, D. Binns, P. Roselt, L. I. Weibe, G. A. McArthur, C. Cullinane, and R. J. Hicks Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging Mol. Cancer Ther., September 1, 2005; 4(9): 1417 - 1422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Taron, Y. Ichinose, R. Rosell, T. Mok, B. Massuti, L. Zamora, J. L. Mate, C. Manegold, M. Ono, C. Queralt, et al. Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas Clin. Cancer Res., August 15, 2005; 11(16): 5878 - 5885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sini, L. Wyder, C. Schnell, T. O'Reilly, A. Littlewood, R. Brandt, N. E. Hynes, and J. Wood The Antitumor and Antiangiogenic Activity of Vascular Endothelial Growth Factor Receptor Inhibition Is Potentiated by ErbB1 Blockade Clin. Cancer Res., June 15, 2005; 11(12): 4521 - 4532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Christensen, P. W. Vincent, W. D. Klohs, D. W. Fry, W. R. Leopold, and W. L. Elliott Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor Mol. Cancer Ther., June 1, 2005; 4(6): 938 - 947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hirata, F. Hosoi, M. Miyagawa, S.-i. Ueda, S. Naito, T. Fujii, M. Kuwano, and M. Ono HER2 Overexpression Increases Sensitivity to Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, through Inhibition of HER2/HER3 Heterodimer Formation in Lung Cancer Cells Cancer Res., May 15, 2005; 65(10): 4253 - 4260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yokoi, P. H. Thaker, S. Yazici, R. R. Rebhun, D.-H. Nam, J. He, S.-J. Kim, J. L. Abbruzzese, S. R. Hamilton, and I. J. Fidler Dual Inhibition of Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor Phosphorylation by AEE788 Reduces Growth and Metastasis of Human Colon Carcinoma in an Orthotopic Nude Mouse Model Cancer Res., May 1, 2005; 65(9): 3716 - 3725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Yoshimoto, K. Kasahara, M. Nishio, T. Hourai, T. Sone, H. Kimura, M. Fujimura, and S. Nakao Changes in Angiogenic Growth Factor Levels After Gefitinib Treatment in Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., May 1, 2005; 35(5): 233 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Herbst, D. H. Johnson, E. Mininberg, D. P. Carbone, T. Henderson, E. S. Kim, G. Blumenschein Jr, J. J. Lee, D. D. Liu, M. T. Truong, et al. Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non-Small-Cell Lung Cancer J. Clin. Oncol., April 10, 2005; 23(11): 2544 - 2555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. W. Park, M. N. Younes, S. A. Jasser, O. G. Yigitbasi, G. Zhou, C. D. Bucana, B. N. Bekele, and J. N. Myers AEE788, a Dual Tyrosine Kinase Receptor Inhibitor, Induces Endothelial Cell Apoptosis in Human Cutaneous Squamous Cell Carcinoma Xenografts in Nude Mice Clin. Cancer Res., March 1, 2005; 11(5): 1963 - 1973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Spano, R. Fagard, J.-C. Soria, O. Rixe, D. Khayat, and G. Milano Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives Ann. Onc., February 1, 2005; 16(2): 189 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P M Harari Epidermal growth factor receptor inhibition strategies in oncology Endocr. Relat. Cancer, December 1, 2004; 11(4): 689 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Matheson, J. P. McNamee, T. Wang, M. A. Alaoui-Jamali, A. M. Tari, and B. J. Jean-Claude The Combi-Targeting Concept: Dissection of the Binary Mechanism of Action of the Combi-Triazene SMA41 in Vitro and Antitumor Activity in Vivo J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1163 - 1170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. H. Kim, G. Ishii, K. Goto, K. Nagai, K. Tsuta, S. Shiono, J. Nitadori, T. Kodama, Y. Nishiwaki, and A. Ochiai Dominant Papillary Subtype Is a Significant Predictor of the Response to Gefitinib in Adenocarcinoma of the Lung Clin. Cancer Res., November 1, 2004; 10(21): 7311 - 7317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. P. J. Leenders, B. Kusters, K. Verrijp, C. Maass, P. Wesseling, A. Heerschap, D. Ruiter, A. Ryan, and R. de Waal Antiangiogenic Therapy of Cerebral Melanoma Metastases Results in Sustained Tumor Progression via Vessel Co-Option Clin. Cancer Res., September 15, 2004; 10(18): 6222 - 6230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lin, S.-C. Tsai, C.-C. Lee, B.-W. Wang, J.-Y. Liou, and K.-G. Shyu Berberine Inhibits HIF-1{alpha} Expression via Enhanced Proteolysis Mol. Pharmacol., September 1, 2004; 66(3): 612 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ono, A. Hirata, T. Kometani, M. Miyagawa, S.-i. Ueda, H. Kinoshita, T. Fujii, and M. Kuwano Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation Mol. Cancer Ther., April 1, 2004; 3(4): 465 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. KUWANO, S. NAKAO, H. YAMAMOTO, M. TSUNEYOSHI, T. YAMAMOTO, M. KUWANO, and M. ONO Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis FASEB J, February 1, 2004; 18(2): 300 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Janmaat and G. Giaccone Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Oncologist, December 1, 2003; 8(6): 576 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ramesh, A. M. Mhashilkar, F. Tanaka, Y. Saito, C. D. Branch, K. Sieger, J. B. Mumm, A. L. Stewart, A. Boquio, L. Dumoutier, et al. Melanoma Differentiation-associated Gene 7/Interleukin (IL)-24 Is a Novel Ligand That Regulates Angiogenesis via the IL-22 Receptor Cancer Res., August 15, 2003; 63(16): 5105 - 5113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Matsuo, H. Sakurai, and I. Saiki ZD1839, a Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Shows Antimetastatic Activity Using a Hepatocellular Carcinoma Model Mol. Cancer Ther., June 1, 2003; 2(6): 557 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Janmaat, F. A. E. Kruyt, J. A. Rodriguez, and G. Giaccone Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer Cells: Limited Antiproliferative Effects and Absence of Apoptosis Associated with Persistent Activity of Extracellular Signal-regulated Kinase or Akt Kinase Pathways Clin. Cancer Res., June 1, 2003; 9(6): 2316 - 2326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nakao, T. Kuwano, T. Ishibashi, M. Kuwano, and M. Ono Synergistic Effect of TNF-{alpha} in Soluble VCAM-1-Induced Angiogenesis Through {alpha}4 Integrins J. Immunol., June 1, 2003; 170(11): 5704 - 5711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Brat and T. B. Mapstone Malignant Glioma Physiology: Cellular Response to Hypoxia and Its Role in Tumor Progression Ann Intern Med, April 15, 2003; 138(8): 659 - 668. [Full Text] [PDF]
|
|
|
|
|
|
S.-J. Kim, H. Uehara, T. Karashima, D. L. Shepherd, J. J. Killion, and I. J. Fidler Blockade of Epidermal Growth Factor Receptor Signaling in Tumor Cells and Tumor-associated Endothelial Cells for Therapy of Androgen-independent Human Prostate Cancer Growing in the Bone of Nude Mice Clin. Cancer Res., March 1, 2003; 9(3): 1200 - 1210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Nahta, G. N. Hortobagyi, and F. J. Esteva Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention Oncologist, February 1, 2003; 8(1): 5 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. O'Reilly Targeting Multiple Biological Pathways as a Strategy to Improve the Treatment of Cancer Clin. Cancer Res., November 1, 2002; 8(11): 3309 - 3310. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ieki, E. Saitoh, and M. Shibuya Acute lung injury as a possible adverse drug reaction related to gefitinib Eur. Respir. J., January 1, 2002; 22(1): 179 - 181. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
